Alaunos Therapeutics Inc. stocks have been trading up by 46.25 percent amid heightened optimism over its oncology pipeline prospects.
Click Here for a Millionaire's POV on Trading TCRT
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- TCRT has ripped from the $1.60s on the daily chart to the mid‑$2s intraday, showing aggressive momentum and expanding ranges.
- Alaunos Therapeutics Inc. reports tiny revenue, heavy losses, and negative cash flow, leaving TCRT a pure speculative trading vehicle.
- The balance sheet shows just $124,000 in cash and negative working capital, raising dilution and financing risk for TCRT traders.
- Intraday five‑minute candles on TCRT reveal violent swings over $0.50 in minutes, rewarding disciplined momentum trading and punishing hesitation.
Live Update At 07:47:12 EDT: On Friday, September 18, 2026 Alaunos Therapeutics Inc. stock [NASDAQ: TCRT] is trending up by 46.25%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
TCRT is trading like a classic low‑float biotech speculation, not a steady cash machine. On the fundamentals, Alaunos Therapeutics Inc. booked only about $5,000 in revenue, yet carries a sky‑high price‑to‑sales ratio north of 1,500. That tells traders the market is pricing TCRT almost entirely on hope for future science, not current business strength.
Losses are deep. Recent quarterly numbers show TCRT with roughly -$0.41 in EPS and net income around -$952,000. Operating cash flow is about -$300,000, with free cash flow also -$300,000. For a tiny company, that burn rate matters. Alaunos Therapeutics Inc. ended the period with only $124,000 in cash and negative working capital of about -$198,000, meaning near‑term liquidity is tight.
More Breaking News
- Rocket Lab Stock Extends Rally As Backlog And Deals Surge
- FICO Stock Plunges As Mortgage Rules Rattle Core Franchise
- HDFC Bank (HDB) Balances CEO Search, Lawsuit, And Choppy ADR Action
- MEDS Stock Rockets As Helomics Deal And GLP‑1 App Ignite Trading
Leverage is not the main problem; TCRT shows no long‑term debt and modest payables. The bigger issue is sustainability. Return on equity and return on assets are both deeply negative, signaling that Alaunos Therapeutics Inc. is not generating economic value today. For traders, that backdrop reinforces TCRT as a technical and sentiment‑driven trade, where chart levels and volume matter more than earnings growth.
Why Traders Are Watching TCRT’s Wild Price Action
On the chart, TCRT has turned into a rollercoaster. Daily data show Alaunos Therapeutics Inc. basing in the mid‑$1 range, then suddenly stretching to much higher levels on heavy trading. Just days ago, TCRT closed around $1.60, after oscillating between $1.28 and $1.79 over a few weeks. That’s already high beta behavior. The real story is what happened intraday.
The five‑minute chart shows TCRT exploding from under $2 at 04:00 to a spike high above $3 shortly after 05:00. That’s a move of more than 50% in about an hour. Candles between 04:35 and 05:10 on Alaunos Therapeutics Inc. show repeated surges and sharp pullbacks — a textbook playground for momentum traders who study level‑2, volume, and risk management.
Notice how TCRT pushes to $3.14, then fades back into the mid‑$2s, consolidates, and keeps swinging in $0.20–$0.30 ranges every few minutes. That tells you algos and short‑term traders are battling over every tick. Alaunos Therapeutics Inc. is offering liquidity and ranges that small‑account traders dream about, but only if they respect the volatility.
TCRT’s fundamentals — minimal revenue, big accumulated deficit, and heavy negative returns — mean longer‑term players are not anchoring the stock. Price is being set by trading flows, not balance‑sheet strength. That’s why TCRT can squeeze hard on any burst of volume, and why it can also unwind fast when momentum stalls. For active traders tracking Alaunos Therapeutics Inc., this is a pure pattern and psychology game.
Conclusion
TCRT sits at the intersection of weak fundamentals and explosive price action. Alaunos Therapeutics Inc. has just over $1.5M in total assets, only $124,000 in cash, and roughly $864,000 in liabilities. With a current ratio below 1 and a quick ratio near 0.1, TCRT is under real balance‑sheet pressure. That often leads to capital raises or strategic moves, and traders know those events can reset price quickly.
Yet the tape doesn’t lie. Alaunos Therapeutics Inc. is attracting attention because the chart offers opportunity. A run from sub‑$2 to over $3 in premarket, followed by wide five‑minute candles, gives TCRT day traders multiple entries and exits if they stay disciplined. The key is treating Alaunos Therapeutics Inc. as what it is right now: a speculative biotech ticker driven by momentum, not by stable cash flows. In that context, setup quality matters as much as the underlying story. As Tim Bohen, lead trainer with StocksToTrade says, “A good trade setup checks all the boxes—volume, trend, catalyst. Don’t trade if you’re missing pieces of the puzzle.” TCRT’s recent action shows how quickly a chart can move when those elements line up, but also how fast it can fade when they don’t.
For newer traders, TCRT is a live case study in why risk management matters more than any single hot stock. As Tim Sykes likes to hammer home, “Cut losses quickly; small losses are fine, big losses are unacceptable.” Applied to TCRT, that means respecting your stops, sizing down into the volatility, and trading the price action — not a story in your head. This analysis is for educational and research purposes only, but the lessons from Alaunos Therapeutics Inc. are real for anyone serious about trading.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.